Reaction

Colectomy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,531 reports · 60 co-occurring drugs

As of the last recalculation, Colectomy appears in 5,531 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 29.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Vedolizumab	601	29.3	29.5
Infliximab	1,191	25.9	26.0
Upadacitinib	383	18.9	19.0
Risankizumab-Rzaa	346	16.9	17.0
Ustekinumab	339	13.2	13.3
Infliximab-Dyyb	92	12.0	12.1
Mercaptopurine	47	10.3	10.3
Azathioprine	205	9.1	9.1
Adalimumab-Fkjp	98	8.1	8.1
Adalimumab-Aaty	99	8.0	8.0
Adalimumab	1,210	8.0	8.0
Adalimumab-Adaz	102	7.4	7.4
Cholestyramine	21	6.6	6.6
Mesalamine	95	6.5	6.5
Golimumab	120	5.4	5.4
Diphenoxylate Hydrochloride And Atropine Sulfate	18	5.0	5.0
Loperamide Hydrochloride And Dimethicone	33	3.9	3.9
Tofacitinib Citrate	13	3.7	3.7
Budesonide	58	3.7	3.7
Pancrelipase	38	3.7	3.7
Dicyclomine Hydrochloride	14	3.7	3.7
Ursosiol	19	3.7	3.7
Prednisone	429	3.4	3.4
Ursodiol	19	3.3	3.3
Hyoscyamine Sulfate	8	3.3	3.3
Psyllium Husk	8	3.1	3.1
Loperamide Hydrochloride	36	3.0	3.0
Terbinafine Hydrochloride	7	3.0	3.0
Iron	52	2.9	2.9
Rizatriptan Benzoate	7	2.6	2.6
Minocycline	8	2.6	2.6
Linaclotide	18	2.5	2.5
Iron Sucrose	6	2.4	2.4
Tofacitinib	110	2.3	2.3
Teduglutide	8	2.2	2.2
Panitumumab	8	1.9	1.9
Imatinib Mesylate	14	1.9	1.9
Bosentan	25	1.9	1.9
Certolizumab Pegol	57	1.8	1.8
Bimekizumab	10	1.8	1.8
Fluticasone Propionate And Salmeterol	19	1.7	1.7
Niraparib	10	1.7	1.7
Umeclidinium	4	1.7	1.7
Ipilimumab	19	1.7	1.7
Dronedarone	4	1.5	1.5
Ranolazine	4	1.4	1.4
Nintedanib	12	1.4	1.4
Umeclidinium Bromide And Vilanterol Trifenatate	5	1.1	1.1
Relugolix	7	1.1	1.1
Patiromer	4	1.1	1.1
Cetuximab	9	1.1	1.1
Glecaprevir And Pibrentasvir	3	1.0	1.0
Dornase Alfa	5	1.0	1.0
Orlistat	6	0.9	0.9
Natalizumab	42	0.9	0.9
Copper	9	0.8	0.8
Guselkumab	6	0.6	0.6
Valbenazine	4	0.6	0.6
Droxidopa	3	0.5	0.5
Galcanezumab-Gnlm	4	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.